{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T09:02:48Z","timestamp":1785229368230,"version":"3.55.0"},"reference-count":16,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"DOI":"10.2340\/actadv.v106.adv-2026-0693","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T08:17:25Z","timestamp":1785226645000},"source":"Crossref","is-referenced-by-count":0,"title":["Fungal Skin Infections in Cutaneous T-cell Lymphoma Patients under Mogamulizumab Treatment"],"prefix":"10.2340","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6456-2681","authenticated-orcid":false,"given":"Susanne","family":"Melchers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlis","family":"Gerigk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maren","family":"Hedke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christel","family":"Wei\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0220-0551","authenticated-orcid":false,"given":"Jan P.","family":"Nicolay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"163717","doi-asserted-by":"crossref","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IB de O, Berti E, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: Lymphoid neoplasms. Leukemia 2022; 36: 1720\u20131748.","DOI":"10.1038\/s41375-022-01620-2"},{"key":"163718","doi-asserted-by":"crossref","unstructured":"Dobos G, Pohrt A, Ram-Wolff C, Lebb\u00e9 C, Bouaziz JD, Battistella M, et al. Epidemiology of cutaneous T-cell lymphomas: a systematic review and meta-analysis of 16,953 patients. Cancers 2020; 12: 12.","DOI":"10.3390\/cancers12102921"},{"key":"163719","doi-asserted-by":"crossref","unstructured":"Blaizot R, Ouattara E, Fauconneau A, Beylot-Barry M, Pham-Ledard A. Infectious events and associated risk factors in mycosis fungoides\/S\u00e9zary syndrome: a retrospective cohort study. Br J Dermatol 2018; 179: 1322\u20131328.","DOI":"10.1111\/bjd.17073"},{"key":"163720","doi-asserted-by":"crossref","unstructured":"Martin SJ, Duvic M. Prevalence and treatment of palmoplantar keratoderma and tinea pedis in patients with S\u00e9zary syndrome. Int J Dermatol 2012; 51: 1195\u20131198.","DOI":"10.1111\/j.1365-4632.2011.05204.x"},{"key":"163721","doi-asserted-by":"crossref","unstructured":"Lakhani SJ, Bilimoria F, Lakhani JD. Adverse effects of steroid use in dermatophytic infections: a cross sectional study. J Integr Health Sci 2017; 5: 63.","DOI":"10.4103\/2347-6486.240248"},{"key":"163722","doi-asserted-by":"crossref","unstructured":"Priyanka A N, K Kaviarasan P, Kannambal K, Poorana B, AbhiramiC. Clinicoepidemiological profile of steroid modified dermatophytosis following abuse of irrational combination of topical corticosteroid containing preparations (ICSP). IJCED 2020; 6: 318\u2013324.","DOI":"10.18231\/j.ijced.2020.064"},{"key":"163723","doi-asserted-by":"crossref","unstructured":"Latzka J, Assaf C, Bagot M, Cozzio A, Dummer R, Guenova E, et al. EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome - update 2023. Eur J Cancer 2023; 195: 113343.","DOI":"10.1016\/j.ejca.2023.113343"},{"key":"163724","doi-asserted-by":"crossref","unstructured":"Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol 2018; 19: 1192\u20131204.","DOI":"10.1016\/S1470-2045(18)30379-6"},{"key":"163725","doi-asserted-by":"crossref","unstructured":"Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, et al. The international consensus classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee. Blood 2022; 140: 1229\u20131253.","DOI":"10.1182\/blood.2022015851"},{"key":"163726","doi-asserted-by":"crossref","unstructured":"Allen PB, Switchenko J, Ayers A, Kim E, Lechowicz MJ. Risk of bacteremia in patients with cutaneous T-cell lymphoma (CTCL). Leuk Lymphoma 2020; 61: 2652\u20132658.","DOI":"10.1080\/10428194.2020.1779259"},{"key":"163727","doi-asserted-by":"crossref","unstructured":"Wu S, Xu Y, Yang L, Guo L, Jiang X. Short-term risk and long-term incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Front Immunol 2023; 14: 1294416.","DOI":"10.3389\/fimmu.2023.1294416"},{"key":"163728","doi-asserted-by":"crossref","unstructured":"Beylot-Barry M, Quereux G, Nardin C, Duval-Modeste AB, Dereure O, Dalac-Rat S, et al. Effectiveness of mogamulizumab in patients with Mycosis Fungoides or S\u00e9zary syndrome: a multicentre, retrospective, real-world French study. J Eur Acad Dermatol Venereol 2023; 37: 1777\u20131784.","DOI":"10.1111\/jdv.19134"},{"key":"163729","doi-asserted-by":"crossref","unstructured":"Molloy K, Vico C, Ortiz-Romero PL, Scarisbrick JJ. Real-world experience of using mogamulizumab in relapsed\/refractory mycosis fungoides\/S\u00e9zary syndrome. Br J Dermatol 2021; 184: 978\u2013981.","DOI":"10.1111\/bjd.19720"},{"key":"163730","doi-asserted-by":"crossref","unstructured":"Jfri A, Virgen CA, Tawa M, Giobbie-Hurder A, Kupper TS, Fisher DC, et al. Prevalence and implications of mogamulizumab-induced immune-related adverse events in mycosis fungoides\/S\u00e9zary syndrome; a single-center experience. J Am Acad Dermatol 2023; 89: 1044\u20131047.","DOI":"10.1016\/j.jaad.2023.05.082"},{"key":"163731","doi-asserted-by":"crossref","unstructured":"Assaf C, Booken N, Dippel E, Dobos G, Eich HT, Klemke CD, et al. Practical recommendations for therapy and monitoring of mogamulizumab patients in Germany. J Dtsch Dermatol Ges 2025; 23: 341\u2013354.","DOI":"10.1111\/ddg.15639"},{"key":"163732","doi-asserted-by":"crossref","unstructured":"Drgona L, Gudiol C, Lanini S, Salzberger B, Ippolito G, Mikulska M. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4). Clin Microbiol Infect 2018; 24 Suppl 2: S83\u2013S94.","DOI":"10.1016\/j.cmi.2018.03.022"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46595\/54901","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46595\/54902","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46595\/54903","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46595\/54901","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T08:17:30Z","timestamp":1785226650000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/46595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":16,"URL":"https:\/\/doi.org\/10.2340\/actadv.v106.adv-2026-0693","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,28]]}}}